Wednesday, January 28, 2015 10:21:10 AM
You have stated that if KBLB were receiving revenues from the production and sale of MS it would have to be shown in the filings.
This is partly true, but you are confused about the timing and place ofsuch an announcement.
First, you are confusing the S-1 with 10K and 10Q.
Forms 10K and 10Q report the most current company financials.
The S-1 is a statement in support of a new stock registration.
Any financial information contained in the S-1 can be based upon recently reported historical financials.
It most certainly would not be the place to report new financial information not yet released / reported on forms 10 and 8.
The last 10Q was filed on October 23rd and covered the period ending on 9/30/2014 (the 3rd quarter).
Any financial information in the S-1 need not be any more current than this.
There is no 10Q quarterly report required for the 4th quarter.
The next financials report will bw part of the 10K that will be filed
sometime in April of this year.
Therefor KBLB may have been receiving revenues since 10/1/2014 and would not be required to report them until ~4/15/2015
Current information CAN be included in any 10 or 8 report, but it is not required.
SO, If KBLB is earning revenue right now we could hear about it tomorrow,
but they will not be Required to report it until April.
Mike L.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM